Literature DB >> 33338327

Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer.

Sara Sf Al-Badran1, Lauren Grant1, Maejoy V Campo1, Jitwadee Inthagard1, Kathryn Pennel1, Jean Quinn1, Prakash Konanahalli2, Liam Hayman1, Paul G Horgan3, Donald C McMillan3, Campbell Sd Roxburgh3, Antonia Roseweir1, James H Park3, Joanne Edwards1.   

Abstract

The tumour microenvironment is an important factor for colorectal cancer prognosis, affecting the patient's immune response. Immune checkpoints, which regulate the immune functions of lymphocytes, may provide prognostic power. This study aimed to investigate the prognostic value of the immune checkpoints TIM-3, LAG-3 and PD-1 in patients with stage I-III colorectal cancer. Immunohistochemistry was employed to detect TIM-3, LAG-3, PD-1 and PD-L1 in 773 patients with stage I-III colorectal cancer. Immune checkpoint protein expression was assessed in tumour cells using the weighted histoscore, and in immune cells within the stroma using point counting. Scores were analysed for associations with survival and clinical factors. High tumoural LAG-3 (hazard ratio [HR] 1.45 95% confidence interval [CI] 1.00-2.09, p = 0.049) and PD-1 (HR 1.34 95% CI 1.00-1.78, p = 0.047) associated with poor survival, whereas high TIM-3 (HR 0.60 95% CI 0.42-0.84, p = 0.003), LAG-3 (HR 0.58 95% CI 0.40-0.87, p = 0.006) and PD-1 (HR 0.65 95% CI 0.49-0.86, p = 0.002) on immune cells within the stroma associated with improved survival, while PD-L1 in the tumour (p = 0.487) or the immune cells within the stroma (p = 0.298) was not associated with survival. Furthermore, immune cell LAG-3 was independently associated with survival (p = 0.017). Checkpoint expression scores on stromal immune cells were combined into a Combined Immune Checkpoint Stromal Score (CICSS), where CICSS 3 denoted all high, CICSS 2 denoted any two high, and CICSS 1 denoted other combinations. CICSS 3 was associated with improved patient survival (HR 0.57 95% CI 0.42-0.78, p = 0.001). The results suggest that individual and combined high expression of TIM-3, LAG-3, and PD-1 on stromal immune cells are associated with better colorectal cancer prognosis, suggesting there is added value to investigating multiple immune checkpoints simultaneously.
© 2020 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland & John Wiley & Sons, Ltd.

Entities:  

Keywords:  LAG-3; PD-1; TIM-3; colorectal cancer; immune checkpoint; prognosis; stromal immune cells; tumour microenvironment

Mesh:

Substances:

Year:  2020        PMID: 33338327      PMCID: PMC7869939          DOI: 10.1002/cjp2.193

Source DB:  PubMed          Journal:  J Pathol Clin Res        ISSN: 2056-4538


  51 in total

1.  High Ki67 expression is an independent good prognostic marker in colorectal cancer.

Authors:  Nathaniel Melling; Charlotte Marie Kowitz; Ronald Simon; Carsten Bokemeyer; Luigi Terracciano; Guido Sauter; Jakob Robert Izbicki; Andreas Holger Marx
Journal:  J Clin Pathol       Date:  2015-08-17       Impact factor: 3.411

2.  The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer.

Authors:  J H Park; C H Richards; D C McMillan; P G Horgan; C S D Roxburgh
Journal:  Ann Oncol       Date:  2014-01-23       Impact factor: 32.976

3.  Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

Authors:  Michael J Overman; Ray McDermott; Joseph L Leach; Sara Lonardi; Heinz-Josef Lenz; Michael A Morse; Jayesh Desai; Andrew Hill; Michael Axelson; Rebecca A Moss; Monica V Goldberg; Z Alexander Cao; Jean-Marie Ledeine; Gregory A Maglinte; Scott Kopetz; Thierry André
Journal:  Lancet Oncol       Date:  2017-07-19       Impact factor: 41.316

4.  The clinical utility of the local inflammatory response in colorectal cancer.

Authors:  Colin H Richards; Campbell S D Roxburgh; Arfon G Powell; Alan K Foulis; Paul G Horgan; Donald C McMillan
Journal:  Eur J Cancer       Date:  2013-10-05       Impact factor: 9.162

5.  The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial.

Authors:  A Huijbers; R A E M Tollenaar; G W v Pelt; E C M Zeestraten; S Dutton; C C McConkey; E Domingo; V T H B M Smit; R Midgley; B F Warren; E C Johnstone; D J Kerr; W E Mesker
Journal:  Ann Oncol       Date:  2012-08-02       Impact factor: 32.976

6.  Detailed analysis of inflammatory cell infiltration in colorectal cancer.

Authors:  J P Väyrynen; A Tuomisto; K Klintrup; J Mäkelä; T J Karttunen; M J Mäkinen
Journal:  Br J Cancer       Date:  2013-09-05       Impact factor: 7.640

7.  Mismatch repair status in patients with primary operable colorectal cancer: associations with the local and systemic tumour environment.

Authors:  James H Park; Arfon G Powell; Campbell S D Roxburgh; Paul G Horgan; Donald C McMillan; Joanne Edwards
Journal:  Br J Cancer       Date:  2016-02-09       Impact factor: 7.640

8.  QuPath: Open source software for digital pathology image analysis.

Authors:  Peter Bankhead; Maurice B Loughrey; José A Fernández; Yvonne Dombrowski; Darragh G McArt; Philip D Dunne; Stephen McQuaid; Ronan T Gray; Liam J Murray; Helen G Coleman; Jacqueline A James; Manuel Salto-Tellez; Peter W Hamilton
Journal:  Sci Rep       Date:  2017-12-04       Impact factor: 4.379

9.  Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.

Authors:  Ameet K Mishra; Tanya Kadoishi; Xiaoguang Wang; Emily Driver; Zhangguo Chen; Xiao-Jing Wang; Jing H Wang
Journal:  Oncotarget       Date:  2016-12-06

10.  Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

Authors:  Shohei Koyama; Esra A Akbay; Yvonne Y Li; Grit S Herter-Sprie; Kevin A Buczkowski; William G Richards; Leena Gandhi; Amanda J Redig; Scott J Rodig; Hajime Asahina; Robert E Jones; Meghana M Kulkarni; Mari Kuraguchi; Sangeetha Palakurthi; Peter E Fecci; Bruce E Johnson; Pasi A Janne; Jeffrey A Engelman; Sidharta P Gangadharan; Daniel B Costa; Gordon J Freeman; Raphael Bueno; F Stephen Hodi; Glenn Dranoff; Kwok-Kin Wong; Peter S Hammerman
Journal:  Nat Commun       Date:  2016-02-17       Impact factor: 14.919

View more
  5 in total

Review 1.  Lag3: From Bench to Bedside.

Authors:  Francesca Aroldi; Reem Saleh; Insiya Jafferji; Carmelia Barreto; Chantal Saberian; Mark R Middleton
Journal:  Cancer Treat Res       Date:  2022

Review 2.  Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.

Authors:  Adel Naimi; Rebar N Mohammed; Ahmed Raji; Supat Chupradit; Alexei Valerievich Yumashev; Wanich Suksatan; Mohammed Nader Shalaby; Lakshmi Thangavelu; Siavash Kamrava; Navid Shomali; Armin D Sohrabi; Ali Adili; Ali Noroozi-Aghideh; Ehsan Razeghian
Journal:  Cell Commun Signal       Date:  2022-04-07       Impact factor: 5.712

Review 3.  The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis.

Authors:  Maria Wozniakova; Jozef Skarda; Milan Raska
Journal:  Pathol Oncol Res       Date:  2022-07-21       Impact factor: 2.874

4.  HAMP as a Prognostic Biomarker for Colorectal Cancer Based on Tumor Microenvironment Analysis.

Authors:  Fang-Ze Wei; Shi-Wen Mei; Zhi-Jie Wang; Jia-Nan Chen; Fu-Qiang Zhao; Juan- Li; Ti-Xian Xiao; Wei Zhao; Yun-Bin Ma; Wei Yuan; Qian Liu
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

Review 5.  New Potential Immune Biomarkers in the Era of Precision Medicine: Lights and Shadows in Colorectal Cancer.

Authors:  Angela Damato; Martina Rotolo; Francesco Caputo; Eleonora Borghi; Francesco Iachetta; Carmine Pinto
Journal:  Life (Basel)       Date:  2022-07-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.